Germany Diabetes Device Market Forecast Report by Types (Self-Monitoring Devices, Continuous Glucose-Monitoring Devices, Insulin Pumps, Insulin Pens), End User (Hospitals, Diagnostics Centers, Homecare) and Company Analysis 2024-2032
Buy NowGermany Diabetes Device Market Size
Germany Diabetes Device market is expected to reach US$ 1.39 Billion in 2023 to US$ 2.62 Billion by 2032, with a CAGR of 7.30 % from 2024 to 2032. The wide variety of applications available for diabetes helps with insulin dosage, blood glucose control quality assessment, and adoption of lifestyle strategies for diabetes prevention and treatment. Further advancements include automatic insulin titration software, remote coaching, and blood glucose monitoring integrated with insulin calculators. These tools help patients with poorly controlled diabetes receive the extra support they need to improve important outcomes, which will increase market prospects going forward.
Germany Diabetes Device Overview
The market for diabetic devices in Germany is one that is changing quickly due to rising diabetes prevalence and rising demand for cutting-edge management and monitoring tools. The nation is proud of its strict reimbursement laws and comprehensive healthcare system, which promote technological innovation and uptake. Prominent firms in the industry, including as Abbott, Medtronic, and Roche, provide a variety of products, such as blood glucose meters, insulin pumps, and continuous glucose monitors (CGMs).
Current patterns point to a move toward digital health solutions that improve patient interaction and enable distant monitoring, such telemedicine and smartphone apps. Growth in the market is further supported by the German government's emphasis on preventative care and the management of chronic diseases. The use of artificial intelligence and data analytics into device functionality is anticipated to revolutionize treatment techniques and greatly enhance patient outcomes as diabetes care becomes more individualized.
The German Diabetes Centre (DDZ) estimates that 8.5 million Germans suffer from diabetes. Over the next 20 years, the number of persons in Germany who have Type 2 diabetes will rise. Up to twelve million people may experience metabolic diseases by 2040, according to DDZ research.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 1.39 Billion |
|
Market Forecast in 2032 |
US$ 2.62 Billion |
|
Market Growth Rate (2024-2032) |
7.30% |
Growth Drivers for the Germany Diabetes Device Market
Insulin delivery device technology has advanced, enabling safer and more precise insulin administration
Diabetes care is being completely transformed by technological developments in insulin delivery systems, smart gadgets, and continuous glucose monitoring (CGM). A growing number of patients wanting improved control over their condition are drawn to diabetes care because to these developments, which improve accuracy, ease, and user experience.
The first and only infusion set that may be worn for up to seven days, the Medtronic Extended infusion set was introduced by Medtronic in a few European countries in April 2021. A set change is usually necessary for an infusion set, which is a tubing that transports insulin from the pump to the body every few days. With this breakthrough, patients can safely continue on insulin pump therapy with fewer interruptions and insertions while also enjoying greater convenience and comfort in their diabetes management routine. An infusion set can now be worn for twice as long. All MiniMed insulin pumps from the 600 and 700 series are compatible with this set.
Placing Personalized Medicine Foremost
Personalized medicine is revolutionizing diabetes care by applying artificial intelligence and data analytics to therapeutic techniques. Healthcare professionals can adapt insulin dosages and monitoring techniques with tailored treatment plans to each patient's unique requirements, lifestyle, and genetic makeup. Better health results result from this individualized strategy, which increases patient involvement and adherence. Furthermore, continuous data collection and real-time insights are made possible by the integration of cutting-edge technologies into diabetes devices, which helps to further improve treatment approaches. The market is expanding as a result of the increasing adoption and usage of these cutting-edge gadgets as patients experience better condition management.
Germany Diabetes Device Company Analysis
The major participants in the Germany Diabetes Device market includes Abbott Laboratories, Roche, Dexcom Inc., Medtronic, Novo Nordisk A/S, Eli Lilly, Sanofi.
Germany Diabetes Device Company News
In February 2024, Germany has seen the release of Dexcom's real-time continuous glucose monitoring (CGM) device, the Dexcom ONE+. This device enhances comfort and convenience for diabetes treatment by enabling users to wear the sensor in three different body locations and continuously check their blood sugar levels.
In May 2023, in a study published in Diabetes Therapy, LifeScan IP Holdings, LLC examined real-world data from a mobile app and blood glucose meter that were enabled via Bluetooth. The study looked at long-term outcomes over a period of 180 days and offered insightful information for people with diabetes.
Types- Industry is divided into 4 viewpoints:
- Self-Monitoring Devices
- Continuous Glucose-Monitoring Devices
- Insulin Pumps
- Insulin Pens
End User - Industry is divided into 3 viewpoints:
- Hospitals
- Diagnostics Centers
- Homecare
All companies have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis
- Abbott Laboratories
- Roche
- Dexcom Inc.
- Medtronic
- Novo Nordisk A/S
- Eli Lilly
- Sanofi
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered | Types and End User |
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Germany Diabetes Devices Market
6. Germany Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes
7. Market Share Analysis
7.1 By Types
7.2 By End User
8. Types
8.1 Self-Monitoring Devices
8.1.1 Test Strips
8.1.2 Lancets
8.1.3 Blood Glucose Meters
8.2 Continuous Glucose-Monitoring Devices
8.2.1 Sensors
8.2.2 Transmitter
8.2.3 Receiver
8.3 Insulin Pumps
8.3.1 Patch Pumps
8.3.2 Tethered Pumps
8.3.3 Consumables
8.4 Insulin Pens
8.4.1 Disposable Insulin Pen
8.4.2 Reusable Insulin Pen
9. End User
9.1 Hospitals
9.2 Diagnostics Centers
9.3 Homecare
10. Porters Five Forces
10.1 Bargaining Power of Buyer
10.2 Bargaining Power of Supplier
10.3 Threat of New Entrants
10.4 Rivalry among Existing Competitors
10.5 Threat of Substitute Products
11. SWOT Analysis
11.1 Strengths
11.2 Weaknesses
11.3 Opportunities
11.4 Threats
12. Reimbursement Policies
12.1 CGM Devices in Germany
12.2 Blood Glucose Devices in Germany
12.3 Insulin Pump Products in Germany
12.4 Insulin Pen in Germany
13. Key Players Analysis
13.1 Abbott Laboratories
13.1.1 Overviews
13.1.2 Key Person
13.1.3 Recent Developments & Strategies
13.1.4 Product Portfolio & Product Launch in Last 1 Year
13.1.5 Revenue
13.2 Roche
13.2.1 Overviews
13.2.2 Key Person
13.2.3 Recent Developments & Strategies
13.2.4 Product Portfolio & Product Launch in Last 1 Year
13.2.5 Revenue
13.3 Dexcom Inc.
13.3.1 Overviews
13.3.2 Key Person
13.3.3 Recent Developments & Strategies
13.3.4 Product Portfolio & Product Launch in Last 1 Year
13.3.5 Revenue
13.4 Medtronic
13.4.1 Overviews
13.4.2 Key Person
13.4.3 Recent Developments & Strategies
13.4.4 Product Portfolio & Product Launch in Last 1 Year
13.4.5 Revenue
13.5 Novo Nordisk A/S
13.5.1 Overviews
13.5.2 Key Person
13.5.3 Recent Developments & Strategies
13.5.4 Product Portfolio & Product Launch in Last 1 Year
13.5.5 Revenue
13.6 Eli Lilly
13.6.1 Overviews
13.6.2 Key Person
13.6.3 Recent Developments & Strategies
13.6.4 Product Portfolio & Product Launch in Last 1 Year
13.6.5 Revenue
13.7 Sanofi
13.7.1 Overviews
13.7.2 Key Person
13.7.3 Recent Developments & Strategies
13.7.4 Product Portfolio & Product Launch in Last 1 Year
13.7.5 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com